 Cytovia Therapeutics Inc and Cellectis SA NASDAQ: CLLS have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells. The expanded agreement will include a new CAR target and development in China by Cytovias joint venture entity, CytoLynx Therapeutics. 